Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1627 1629
This examiner grants 62% of resolved cases
Dawanna Shar-Day White is a patent examiner assigned to Art Unit 1627 within Tech Center 1600. The examiner's professional record includes 119 resolved cases. The data indicates an allowance rate of 62.2% for these applications. This figure serves as a primary indicator of the probability of success for cases on this docket. Additionally, the median days to allowance is 1264, which establishes a specific timeframe for the prosecution process. These metrics offer a foundational understanding of the examiner's approach to patent applications.
The interview lift for this examiner is 23.8%. This 23.8% lift shows the change in the likelihood of allowance when an interview is conducted compared to the 62.2% base rate. With 119 resolved cases, the data provides a view of the examiner's historical performance. The 1264-day median pendency is a key metric for managing client expectations regarding the duration of the patent application process in Tech Center 1600. Practitioners should evaluate the allowance rate and the interview lift to determine the most effective strategy for their specific cases.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18101772 | COMPOUNDS AND METHODS FOR TREATING CANCER | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18891879 | MACROCYCLIC CYCLOPHANES | Non-Final OA | Iowa State University Research Foundation, Inc. |
| 18755002 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | Non-Final OA | VANDERBILT UNIVERSITY |
| 18364200 | CHEMICAL MODIFICATION OF ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF | Non-Final OA | Nautilus Subsidiary, Inc. |
| 18678444 | THERAPEUTIC COMPOUNDS FOR HIV | Non-Final OA | Gilead Sciences, Inc. |
| 18548657 | SUPPRESSION OF COVID-19 REPLICATION BY COVID-19 ENTRY INHIBITORS | Final Rejection | THE CURATORS OF THE UNIVERSITY OF MISSOURI |
| 18840040 | METHODS OF TREATING, AMELIORATING, OR PREVENTING HEART FAILURE, AND METHODS OF PROMOTING HEART MUSCLE GROWTH | Non-Final OA | Yale University |
| 18837245 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | Non-Final OA | BIOGEN MA INC. |
| 18954799 | PIM KINASE INHIBITORS FOR TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS AND FIBROSIS ASSOCIATED WITH CANCER | Non-Final OA | The Research Foundation for The State University of New York |
| 18834350 | IMIDAZOTETRAZINE COMPOUNDS AND TREATMENT OF TMZ-RESISTANT CANCERS | Non-Final OA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS |
| 18857231 | SMALL MOLECULE INDUCERS OF CARDIOMYOCYTES TO IMPROVE CARDIAC STRUCTURE AND FUNCTION | Non-Final OA | UNIVERSITY OF MARYLAND, BALTIMORE |
| 18951962 | GPR88-RECEPTOR-AGONIST | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18816550 | PROCESSES FOR THE PREPARATION OF PHENYLTETRAHYDROFURAN COMPOUNDS | Non-Final OA | Hoffmann-La Roche Inc. |
| 18855162 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETIC STROKE, CONTAINING RAGE ANTAGONIST AND AGE SCAVENGER | Non-Final OA | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18871252 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | Non-Final OA | Biomea Fusion, Inc. |
| 18571213 | SALT OF SELECTIVE FGFR4 INHIBITOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Final Rejection | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. |
| 18860199 | DRUG SUSTAINED-RELEASE TABLET FOR TREATING LIVER DISEASE, PREPARATION METHOD THEREFOR AND USE THEREOF | Non-Final OA | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES |
| 18851294 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF ANXIETY | Non-Final OA | GH RESEARCH IRELAND LIMITED |
| 18798160 | PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | Non-Final OA | Corcept Therapeutics Incorporated |
| 18155115 | METHODS OF TREATING LEPTOMENINGEAL METASTASIS | Non-Final OA | MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES |
| 18257384 | ORAL COMPOSITIONS COMPRISING KETAMINE COMBINED WITH SUBCUTANEAL OR INTRAVENOUS KETAMINE FOR USE IN THE TREATMENT, CONTROL OR PREVENTION OF DEPRESSIVE DISORDERS | Final Rejection | NEUROCENTRX PHARMA LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy